TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)
The TACTIVE-U study, sponsored by Pfizer, is investigating the combination of ARV-471, a novel oral proteolysis targeting chimera, with ribociclib in patients with advanced or metastatic ER+ breast cancer. This combination aims to address a significant unmet need in a market characterized by high competition from existing therapies such as CDK4/6 inhibitors and hormonal treatments. The study's focus on patients who have failed prior treatments positions it strategically within the oncology landscape, potentially enhancing Pfizer's portfolio in breast cancer therapeutics. Successful outcomes could lead to a competitive edge in a lucrative market, with the global breast cancer therapeutics market projected to grow significantly in the coming years.
Indication: Breast Cancer
Modality: small molecule
Target: Estrogen Receptor Positive (ER+) and Proteolysis Targeting Chimera (PROTAC) mechanism.
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Estrogen Receptor Positive (ER+) and Proteolysis Targeting Chimera (PROTAC) mechanism.
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Estrogen Receptor Positive (ER+) and Proteolysis Targeting Chimera (PROTAC) mechanism.
Target normalized: Estrogen Receptor Positive (ER+) and Proteolysis Targeting Chimera (PROTAC) mechanism.